1064P Final results of CA209-9JC: A phase II study of first-line nivolumab in patients with advanced cutaneous squamous cell carcinoma

Munhoz, Rodrigo Ramella; Camargo, Veridiana Pires de; Marta, Guilherme Nader; Queiroz, Marcello Moro; Cury‐Martins, Jade; Nardo, Mirella; Chaul-Barbosa, Caroline; Ricci, Hermínia; Mattos, Marcela Rodrigues de; Menezes, T. A. F. de; Machado, Guilherme Urano; Bertolli, Eduardo; Barros, Milton; Franke, F.; Ferreira, Fábio de Oliveira; Feher, Olavo; Castro, Gilberto de

doi:10.1016/j.annonc.2021.08.1449

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NMSCs harbor features predictive of response to immunotherapy, including high tumor mutational burden (TMB) associated with chronic ultraviolet radiation exposure, and other common risk factors like immunosuppression, as well as viral etiology (Merkel cell polyomavirus in MCC) and advanced patients age [ 114 , 115 , 116 ]. In the past decade, multiple clinical trials confirmed the efficacy of ICIs in NMSCs, mainly in SCC and MCC [ 117 , 118 , 119 , 120 , 121 ]. Moreover, more recently, immunotherapy exhibited clinically meaningful antitumor activity in advanced BCC following progression on first-line hedgehog inhibitor therapy (HHI) [ 122 ].…”

Section: State Of Play Of Immunotherapy In Melanoma and Non-melanoma ...mentioning

confidence: 99%

Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers

Spiliopoulou

Vornicova

Genta

et al. 2023

IJMS

View full text Add to dashboard Cite

Recent advances in treating cutaneous melanoma have resulted in impressive patient survival gains. Refinement of disease staging and accurate patient risk classification have significantly improved our prognostic knowledge and ability to accurately stratify treatment. Undoubtedly, the most important step towards optimizing patient outcomes has been the advent of cancer immunotherapy, in the form of immune checkpoint inhibition (ICI). Immunotherapy has established its cardinal role in the management of both early and late-stage melanoma. Through leveraging outcomes in melanoma, immunotherapy has also extended its benefit to other types of skin cancers. In this review, we endeavor to summarize the current role of immunotherapy in melanoma and non-melanoma skin cancers, highlight the most pertinent immunotherapy-related molecular biomarkers, and lastly, shed light on future research directions.

show abstract

Section: State Of Play Of Immunotherapy In Melanoma and Non-melanoma ...mentioning

confidence: 99%

Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers

Spiliopoulou

Vornicova

Genta

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

Combined Response of Advanced Cutaneous Squamous Cell Carcinoma and Renal Cell Carcinoma to Immunotherapy: A Case Report

et al. 2022

View full text Add to dashboard Cite

Immune checkpoint inhibitors have significantly improved the therapeutic scenario of many different advanced malignancies and could be an effective treatment strategy in synchronous or metachronous tumors. The authors describe the clinical case of a patient who experienced a long-lasting response of his metastatic renal cell carcinoma and an optimal response of his locally advanced cutaneous squamous cell carcinoma to immunotherapy. The systemic treatment was chosen based on a literature review of several clinical reports, since there was no prospective study on anti-PD-1 blockade activity in cutaneous squamous cell carcinoma when the patient started the treatment. This clinical case supports the growing evidence for immunotherapy as a valid treatment option across different types of advanced tumors.

show abstract

1064P Final results of CA209-9JC: A phase II study of first-line nivolumab in patients with advanced cutaneous squamous cell carcinoma

Abstract: Background: There are limited published real-world data on the treatment patterns and outcomes of patients with mCSCC. abstracts Annals of OncologyVolume 32 -Issue S5 -2021 S885

Cited by 2 publications

References 0 publications

Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers

Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers

Combined Response of Advanced Cutaneous Squamous Cell Carcinoma and Renal Cell Carcinoma to Immunotherapy: A Case Report

Contact Info

Product

Resources

About